Karl Womer is a Nephrology physician affiliated with Porter Adventist Hospital. OpenAlex indexes 85 publications with 2,285 citations (h-index 30); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2535 S Downing St Ste 380
Denver, CO 802105850
Telephone
303-778-5797Provider last certified this registry record 12 Jun 2024.
Clinical trials
- Sargramostim for Myeloid Dendritic Cell Deficiency
Sponsor: University of Florida
- Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR
Sponsor: University of Florida
- Sargramostim for Myeloid Dendritic Cell Deficiency
Sponsor: Johns Hopkins University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- CALLIDITAS THERAPEUTICS US INC.Program year20241 payment
- Novartis Pharmaceuticals CorporationProgram year20241 payment
- Alexion Pharmaceuticals, Inc.Program year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
70.2%Statin34.4%Atorvastatin Calcium100%Part D≥26 patientsBeta blocker16.7%Carvedilol62%Metoprolol Tartrate38%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
18.1%Corticosteroid18.1%Prednisone100%Part D≥12 patientsAnti-infectives
7.8%Short-acting sulfonamides7.8%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- New-onset diabetes after kidney transplantation: can the risk be modified by choosing immunosuppression regimen based on pretransplant viral serology?
Nephrology Dialysis Transplantation
2017 - Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients
American Journal of Transplantation
2016
Similar KOLs
Other experts from the same institution or the same specialty.
Douglas G. Adler
Porter Adventist Hospital
Hunter Moore, MD
Porter Adventist Hospital
Daniel Perlman, MD
Porter Adventist Hospital
Todd Miner, MD
Porter Adventist Hospital
Andrew Levey, MD
Tufts Medical Center
Bertram Kasiske, MD
Hennepin Healthcare
Garabed Eknoyan, MD
Baylor College of Medicine
Lawrence Hunsicker, MD
University of Iowa
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”